

Adjuvant rLH to rFSH therapy in GnRH analogue cycles:

What do recent meta-analyses add-up to current understanding?

Johnny S. Younis, Israel

The added value of rLH to rFSH treatment during controlled ovarian hyperstimulation (COH) in assisted reproductive technologies (ART), employing GnRH analogues, is continue to be actively discussed and debated. The main arguments remain whether GnRH analogues employment could cause profound LH suppression that may adversely affect folliculogenesis, steroidogenesis and oocyte competence, impinging on clinical outcome and whether rLH supplementation would void these effects.

My talk will include the following objectives:

1. To point out at various factors that may have contributed to the delay and possibly confusion between practitioners related to LH added value in the ART setting.
2. To look into current evidence exploring the added value of rLH adjuvant therapy to rFSH employing GnRH analogues on clinical pregnancy outcome.
3. To point out groups of women that still lack evidence for the added value of rLH supplementation.
4. To discuss ways that may contribute to the debate which groups of women may benefit from adjuvant rLH therapy.